Compare ARK Genomic Revolution ETF (ARKG) vs Expeditors International of Wshngtn Inc (EXPD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Expeditors International of Wshngtn Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while Expeditors International of Wshngtn Inc trades at $172.02 (market cap $22.50B). The key difference: Expeditors International of Wshngtn Inc pays a 0.94% dividend while ARK Genomic Revolution ETF pays none, and Expeditors International of Wshngtn Inc is trading nearer its 52-week high, ARK Genomic Revolution ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | EXPD | |
|---|---|---|
Sector | Sector/Thematic | Industrials |
52-Week High | $43.57 | $172.02 |
52-Week Low | $23.09 | $111.37 |
Market Cap | — | $22.50B |
Enterprise Value | — | $21.75B |
Dividend Yield | — | 0.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
EXPD trades at $172.02, near its R1 resistance of $173, with a bullish technical outlook supported by moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $1.71 surpassing the $1.33 expectation. Revenue growth remains steady, reaching $11.07B in 2025, while maintaining strong profitability with a 36.59% ROE. Recent news highlights momentum from e-commerce demand and strategic focus on supply chain management.
The stock presents growth potential driven by earnings momentum and solid fundamentals, but faces headwinds from analyst skepticism (only 12% buy ratings) and valuation concerns with a P/E of 27.79 above industry averages. Key risks include freight market volatility and geopolitical supply chain pressures. The consensus price target of $159 suggests limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →
